Androgen Suppression With Abiraterone, Leuprolide, PARP Inhibitor and Stereotactic Radiotherapy in Prostate Cancer (ASCLEPIuS)
Clinicaltrials.gov identifier:
NCT04194554
Newly diagnosed prostate cancer grade group 3-5
Androgen Suppression With Abiraterone, Leuprolide, PARP Inhibitor and Stereotactic Radiotherapy in Prostate Cancer (ASCLEPIuS)
About the Study
This study is no longer enrolling patients.
This study will look at treating men with high risk cancer using the , combined with stereotactic body radiotherapy (SBRT), , leuprolide, and prednisone. Phase 1 of this study will look at the best dose of for this treatment combination. The phase 2 portion of this study will look at the 3-year recurrence free-survival rate of the patients who received this combined therapy.
This study is no longer enrolling patients.
This study is no longer enrolling patients.